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ABSTRACT 
Objective: To evaluate the potential of protease producing organism for the production of Angiotensin I–converting enzyme (ACE) inhibitor by 
fermentation of various protein substrates. 
Methods: Bacterial strains were isolated from cow milk collected in Coimbatore, Tamil Nadu, India by using serial dilution technique, plated on 
nutrient agar medium. The identity of the strain was ascertained by 16s rRNA gene sequencing method and was submitted to the NCBI GenBank 
nucleotide database. Various substrates were screened for ACE inhibitor production by the fermentation with the isolated strain. 
Results: The isolated coded as BUCTL09, which showed a significant zone of clearance was selected and identified as Micrococcus luteus 
(KF303592.1). Among the seven substrates, only beef extract fermented broth showed an inhibition of 79% and was reported as the best substrate. 
Conclusion: In the search for non-toxic, and economic ACE inhibitors as an alternative to the synthetic drugs, many natural ACE inhibitors have 
been isolated from a microbial source. In the present study, isolate BUCTL09 was selected for the production of ACE inhibitor from the beef extract. 
Findings from this study lead us to investigate this potent ACE inhibitor further for its biological properties and to explore the impending efficacy of 
the ACE inhibitor which may conceivably be developed into a prospective drug. 
Keywords: Micrococcus luteus, ACE inhibitor, 16S rRNA gene sequence, Hippuric acid, Beef extract. 
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INTRODUCTION 
Among the bioactive peptides, Angiotensin I–converting enzyme (ACE) 
inhibitory peptides derived from food proteins have attracted 
particular attention and have been studied comprehensively for their 
ability to prevent hypertension. These peptides could be used as a 
potent functional food additive and represent a healthier and natural 
alternative to ACE inhibitor drugs. Selecting the proper enzyme to 
hydrolyze the protein is a key factor in obtaining peptides that exhibit 
greater levels of ACE inhibitory behavior [1]. ACE is a dipeptide 
hydrolase that catalyzes both the formation of the potent 
vasoconstrictor, angiotensin-II (Ang-II), and the deactivation of 
bradykinin, a vasodilator peptide. Therefore, substances such as 
synthesized chemical drugs (e. g., captopril) or natural ACE inhibitory 
peptides can inhibit ACE activity and can cause a drop in blood 
pressure. These findings have been shown in both hypertensive human 
subjects and spontaneous hypertensive rats (SHR) [2]. 
Ang II is the principal biologically active peptide that causes arteriolar 
vasoconstriction and stimulates aldosterone secretion and thus plays 
an important role in hydromineral balance. Ang II has a potential role 
in various aspects of tumor progression and targeting Ang II 
production, or action could prove useful in anticancer therapy [3]. 
Researchers hope a better understanding of the angiogenesis process 
will help them in cancer treatment. There are many reports on ACE 
inhibitory peptides derived from food proteins, their physiological and 
pharmacological effects and their prospects for application in 
preventing hypertension and for therapeutic purposes. This study was 
intended to isolate protease producing organism for the production of 
ACE inhibitor by the fermentation of various proteinaceous substrates. 
MATERIALS AND METHODS 
Isolation of bacteria from milk 
Raw unpasteurized milk samples of the cow were collected from the 
local area of Coimbatore, Tamil Nadu, India. The milk was collected in 
sterile screw cap tubes and processed within 3 h and used for further 
studies. Milk samples were serially diluted and were spread plated on 
nutrient agar medium. The plates were then incubated at 37 ºC for 48-
72 h. Individual colonies with typical characteristics of being small (2-3 
mm diameter) with entire margins were picked from each plate and 
transferred to nutrient agar medium. All isolates were initially 
examined by Gram’s staining, cell morphology, and proteolytic 
properties.  
Screening of protease producing bacteria 
The isolates were screened for protease production by gelatin clear 
zone method using protease specific medium containing KH2PO4 
(0.025 g/l), Yeast extract (0.25 g/l), Gelatin (2.5 g/l), NH4HPO4  (0.025 
g/l), CaCl2  (0.025 g/l), MgSO4 .5H2
Identification of bacteria 
O (0.0125 g/l) and Agar (3.75 g/l). 
The diameters of clear zones were measured after 24 h of incubation at 
37 °C by flooding the plates with mercuric chloride solution [4]. The 
isolate which produced the largest zone was selected for further study. 
Morphological and biochemical characterizations 
Identification of bacteria was performed according to their 
morphological, cultural, physiological and biochemical characteristics 
[5]. Gram’s staining, production of catalase, carbohydrate fermentation 
patterns, growth at 37 °C in nutrient agar medium, methyl red (MR) 
and Voges-Proskauer (VP) test in MR-VP medium and indole 
production in tryptone broth as described by Bergey’s Manual of 
systematic Bacteriology were performed to identify the genus of 
bacteria. 
Molecular characterization of bacteria 
DNA isolation 
Genomic DNA was isolated from the test organism [6]. Amplification of 
16s rRNA gene was done with Universal primers: Forward primer 5’-
GAGTTTGATCCTGGCTCAG-3’; Reverse primer 5’-ACGGCTACCT-TGTT 
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ACGACTT-3’ (Chromous Biotech, Bengaluru, India). The amplification 
of the gene was done as per the table 1. The PCR product was then 
visualized by running in agarose gel electrophoresis (1%). The 
amplicon was then sequenced. 
Polymerase chain reaction (PCR) amplification of the 16s rRNA gene 
The organism was identified with 16S rRNA sequencing method. The 
PCR product was purified and sequenced by using an automatic 
sequencer (ABI 3500xl Genetic Analyzer, Chromous Biotech, 
Bengaluru, India). 
Phylogenetic analysis 
The sequences obtained were aligned using Chromas Lite Version 2.1.1. 
The nucleotide Basic Local Alignment Search tool (BLAST) was 
performed for the amplified sequence using National Center 
Biotechnology Information (NCBI) BLAST 2.2.28 program. The 
sequences producing significant alignment were obtained, and distance 
tree was produced using the BLAST pairwise alignment algorithm. The 
construction of phylogenetic tree was based on fast minimum evolution 
method (table 2).  
The 16S rRNA gene sequence was obtained and was compared with 
those available in the GenBank, EMBL and DJB databases using the 
gapped BLAST 2.0.5 program through the National Center for 
Biotechnology Information server [7]. Sequences were obtained from the 
GeBank database and aligned by using the multisequence alignment 
program Clustal W [8]. Phylogenetic relationships were inferred from 
this alignment by using programs in MEGA software package. The 
phylogenetic tree was constructed by using Neighbour-joining method. 
  
Table 1: PCR reaction conditions 
PCR reaction mixture 31 cycles and final extension at 72 °C for 10 min 
S. No.   
1. 10X Taq buffer 5 µl 
2. dNTP mix (4 mM) 5 µl 
3. Forward primer (5 µm) 5 µl 
4. Reserve primer (5 µm) 5 µl 
5. Genomic DNA template (100 ng/1 µl) 5 µl 
6. Taq DNA polymerase (5 U/µl) 0.4 µl 
7. Nuclease-free water 24.6 µl 
8. PCR program is mentioned as follows  
i. Initial denaturation  96 o 5 min C 
ii. Denaturation  94 o 1 min C 
iii. Annealing  48 o 1 min C 
iv. Extension  72 o 2 min C 
Table 2: Morphological and biochemical properties of strain BUCTL09 
Reactions Observation 
Morphology Cocci 
Gram’s reaction + 
Catalase test + 
Indole - 
Methyl red test - 
Voges-Proskauer - 
Citrate - 
Gas production from glucose + 
Growth at  37º C 
Growth under aerobic condition  + 













Starch Hydrolysis - 
Urease Test + 
Oxidase - 
(+) = positive, (+w) = weakly positive, (-) = negative 
 
Screening of substrate for ACE inhibiting peptide production 
The selected bacterial culture was used to screen a suitable substrate 
for the production of ACE inhibitory peptides. Various protein 
substrates such as beef extract, yeast extract, peptone, milk powder, 
cow milk, goat milk and buffalo milk were amended in the modified M-
9 medium. The cow, goat and buffalo milk were collected from a 
nearest dairy farm and sterilized by heating at 93 °C for 20 min under 
constant stirring for the study. Briefly M-9 medium containing 
MgSO 4 .7H 2 O (0.1482 g/l), KH2 PO 4  (0.3 g/l), FeSO 4 .7H2 O (0.003 
g/l), Na 2 HPO 4  (1.28 g/l), NaCl (0.05 g/l), NH 4 Cl (0.1 g/l), Thiamine 
(0.03 g/l) and CaCl2 .2H2
The production medium was inoculated with a loop full of selected 
bacterial culture from fresh slant (48 h old) and agitated at 150 rpm in 
a rotary shaker. Overnight grown bacterial cultures were harvested by 
centrifugation at 4 °C, 8,000 rpm for 20 min. Extracts fermented by 
different substrates were then screened for ACE inhibition. The protein 
content of the supernatant was estimated by Lowry’s method [9]. 
Based on the observation, the chosen substrate was utilized for further 
studies as ACE inhibitor source. 
O (0.0456 g/l) was supplemented with 
different protein sources like beef extract (2 g/l), yeast extract (2 g/l), 
peptone (2 g/l), commercially available milk powder (2 g/l), cow’s 
milk (100 ml/l), goat’s milk (100 ml/l) and buffalo’s milk (100 ml/l). 
Assay of ACE inhibition 
The ACE inhibitory activity was assayed by the method of Cushman 
and Cheung with some modifications [10]. Hip-His-Leu (HHL) was 
dissolved in 50 mM sodium borate buffer (pH 7.0) containing 1N NaCl. 
Subsequently, 25 µl of 5 mM HHL solution was mixed with 10 µl of beef 
hydrolysate (the pH of which was adjusted to 7.0) and then pre-
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incubated for 10 min at 37 °C. The reaction was initiated by adding 10 
µl of ACE and the mixture was incubated for 30 min at 37 °C. The 
reaction was stopped by adding 200 µl of 1N NaCl. The hippuric acid 
liberated by ACE was extracted with 1 ml ethyl acetate, dissolved by 
adding 1 ml of the buffer after the removal of ethyl acetate by vacuum 
evaporation, ant the optical density was measured at 228 nm. The 
extent of inhibition was calculated using the formula. 
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑜𝑜𝑜𝑜 𝐼𝐼𝐸𝐸ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝐸𝐸𝑖𝑖𝑜𝑜𝐸𝐸 =
(𝐵𝐵 − 𝐴𝐴)
(𝐵𝐵 − 𝐶𝐶)
 𝐸𝐸 100 
Result expressed in percentage 
Where  
A = the optical density in the presence of ACE and ACE inhibitory 
component,  
B = the optical density without an ACE inhibitory component 
C = the optical density without ACE. 
RESULTS AND DISCUSSION 
Isolation of bacteria from cow milk  
Milk samples from cow were collected from local areas of Coimbatore, 
Tamil Nadu, India and processed for the isolation of proteolytic 
bacteria. The microbial colonies were counted in raw milk samples by 
standard plate count. Forty bacterial species were isolated by serial 
dilution technique by plating on nutrient agar (NA). The colonies in 
raw milk sample are expected to be little higher than real microflora. 
This is due to contamination from the animal, especially the exterior of 
the udder and the adjacent areas; bacteria found in manure, soil and 
water may be present in milk [11].  
Identification of protease producing bacteria 
The proteolytic activities of all 40 strains were assayed using gelatin 
agar, which was observed as the diameter of the clear zone. Among the 
forty isolates, the isolate coded as BUCTL09 showed the highest 
proteolytic activity (fig. 1). The best isolate BUCTL09 which produced a 
maximum zone of clearance was selected for further studies.  
The potent bacterial strain was identified based on the morphological 
and biochemical characterization. The bacteria were Gram positive 
cocci (fig. 2). The morphological and biochemical characteristics of the 
test organism are presented in table 2. The morphological and 
biochemical characterization showed that the selected strain was of 
genus Micrococcus sp. classified under the family Micrococcaceae [12]. 
 
Fig. 1: Protease production by BUCTL09 on gelatin agar plate 
 
 
Fig. 2: Microscopic view of gram stained BUCLT09 
 
Molecular characterization of selected bacteria 
The nucleotide amplified the sequence from 16S rRNA gene was found to 
have around 781 bp. The 16S rRNA gene sequence of the isolate was 
compared with available 16S rRNA gene sequence in Gen Bank databases 
using the BLAST search facility in NCBI. In the present study 16S rRNA 
gene sequence of BUCTL09 showed 100% similarity with Micrococcus 
luteus strain. The phylogenetic tree showed the location of isolated strain 
BUCTL09 close to Micrococcus luteus as depicted in fig. 3. 
  
 
Fig. 3: Phylogenetic tree showing the position of BUCTL09 phylogenetic tree (Micrococcus luteus) 
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Screening of substrate for ACE inhibitor production 
Extracts from the chosen fermented substrates were screened for ACE 
inhibition. The ACE inhibition by the bacterial extracts ranged from 
~51 to ~79% (table 3). The minimum inhibition being observed in 
goat milk and the maximum inhibition was exhibited by the beef 
extract. The increasing order of ACE inhibition was goat’s 
milk/peptone/commercial milk powder/buffalo’s milk/cow’s milk/ 
yeast extract and beef extract.  
Beef Extract is derived from the infusion of beef and provides an 
undefined source of nutrients [13], which is a mixture of peptides and 
amino acids, nucleotide fractions, organic acids, minerals and some 
vitamins. Beef extract being produced from meat might have some 
active peptides which might not be present in other protein substrates 
used which justify the present finding [14]. These facts agree with the 
present finding that beef extract was the best source of ACE inhibitory 
peptides and beef extract may be chosen for further ACE inhibitor 
production. 
  
Table 3: Screening of substrate for ACE inhibitor production 
S. No. Substrates ACE enzyme activity inhibition %∆ 
1. Beef extract 79.67±4.73 
 2. Yeast extract 72.00±3.61 
3. Peptone 53.33±1.53 
4. Commercial milk powder 56.67±9.87 
5. Cow’s milk 62.67±4.04 
6. Goat’s milk 51.33±2.52 




Many research groups have combed for ACE inhibitors in microbial 
sources such as Doratomyces putredinis, Nocardia orientalis, 
Streptomycetes, Spiculospora, and Actinomadura. In the present study, 
we isolated and screened a potent ACE inhibitor producing bacteria, 
Micrococcus luteus (accession number Kf303592). ACE inhibitors are 
used in the treatment of heart diseases, hypertension, kidney diseases 
and recent interest has focused on the possible role of these 
compounds in anticancer therapy [15]. The provocative hypothesis 
that ACE is might have a protective role in cancer was first suggested 
by Lever et al. [16] needs to be explored. The search for natural ACE 
inhibitors as alternatives to synthetic drugs is of great interest to 
prevent several side effects, and bioactive peptides are one among the 
best alternatives which can be developed as potential pharmaceutical 
ACE inhibitors. Currently, many studies are being done to search for 
more suitable anticancer agents, including ACE inhibitors, from natural 
products. In the present study, isolate BUCTL09 as M. luteus was 
selected for the isolation of ACE inhibitors. Findings from this study 
may open up the possibilities of more alternatives with ACE inhibitory 
effects with better drug profiles and less adverse side effects. 
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